Circulating tumour cells (CTC) count and prostate-specific antigen (PSA) response measures in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (Doc)

被引：0
|
作者：
Lozano Mejorada, R. [1 ,2 ]
Lorente, D. [3 ]
Castro, E. [4 ,5 ]
Bianchini, D. [6 ,7 ]
Nombela, P. [1 ]
Sandhu, S. K. [8 ]
Romero Laorden, N. [9 ]
Cendon, Y. [1 ]
Sharp, A. [10 ,11 ]
Almagro Casado, E. [12 ]
Pacheco, M. I. [1 ]
Rescigno, P. [13 ]
Llacer, C. [14 ]
Saez, M. [14 ]
Rivera, L. [1 ]
Vitrone, F. [1 ]
Moreno, C. [1 ]
Mateo, J. [15 ]
de Bono, J. S. [16 ,17 ]
Olmos Hidalgo, D. [1 ,5 ]
机构：
[1] Spanish Natl Canc Res Ctr CNIO, Prostate Canc Clin Res Unit, Madrid, Spain
[2] Inst Invest Biomed Malaga IBIMA, Madrid, Spain
[3] Hosp Prov Castellon, Med Oncol, Castellon de La Plana, Spain
[4] Inst Invest Biomed Malaga IBIMA, Prostate Canc Clin Res Unit, Malaga, Spain
[5] Hosp Univ Virgen de la Victoria & Reg Malaga, Malaga, Spain
[6] Inst Canc Res, PCTTG, London, England
[7] Royal Marsden NHS Fdn Trust, London, England
[8] Peter MacCallum Canc Ctr, Div Med Oncol, Melbourne, Vic, Australia
[9] Hosp Univ La Princesa, Med Oncol, Madrid, Spain
[10] Inst Canc Res, Med Oncol, Sutton, Surrey, England
[11] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[12] Hosp Univ Quiron Salud, Med Oncol, Madrid, Spain
[13] Aziende Osped Univ Federico II, Clin Med & Surg, Dept Translat Med Sci, Naples, Italy
[14] Hosp Univ Virgen de la Victoria & Reg Malaga, Med Oncol, Malaga, Spain
[15] Vall dHebron Univ Hosp, Grp Invest Traslac Canc Prostata, Barcelona, Spain
[16] Royal Marsden Fdn Trust, Drug Dev Unit, London, England
[17] Inst Canc Res, London, England
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
889P
引用
收藏
页码：350 / 350
页数：1
相关论文
共 50 条
  • [1] Heterogeneity of prostate-specific membrane antigen (PSMA) expression in classic and apoptotic circulating tumor cells (CTC) in metastatic castration-resistant prostate cancer (mCRPC)
    Autio, Karen A.
    Anand, Aseem
    Krupa, Rachel
    Louw, Jessica
    Arslan, Zaina
    Dittamore, Ryan
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [2] Prostate-specific antigen testing in men with metastatic castration-resistant prostate cancer treated with docetaxel chemotherapy
    Tsai, Yuh-Shyan
    Tzai, Tzong-Shin
    UROLOGICAL SCIENCE, 2015, 26 (04) : 277 - 277
  • [3] Quality of life and survival in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts) treated with docetaxel
    Paredero Perez, I.
    Arnal, M.
    Lorente, D.
    Girones Sarrio, R.
    Lozano Mejorada, R.
    Romero Laorden, N.
    Llacer Perez, C.
    Castro Marcos, E.
    Olmos, D.
    Sanchez Hernandez, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S526 - S526
  • [4] Real-world analysis of prostate-specific antigen (PSA) outcomes among patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA)
    Freedland, Stephen J.
    Schultz, Neil M.
    Coutinho, Anna D.
    Fuldeore, Rupali
    Hedlund, Nancy
    Feng, Qi
    Ramaswamy, Krishnan
    Hong, Agnes
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [5] Assessment of prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) after docetaxel (DOC).
    Cavaliere, Carla
    Caffo, Orazio
    Ortega, Cinzia
    D'aniello, Carmine
    Di Napoli, Marilena
    Cecere, Sabrina Chiara
    Della Pepa, Chiara
    Crispo, Anna
    Maines, Francesca
    Ruatta, Fiorella
    Iovane, Gelsomina
    Montella, Maurizio
    Pignata, Sandro
    Facchini, Gaetano
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] The expression of prostate-specific membrane antigen in circulating tumor cells (CTC) of castration-resistant prostate cancer: The association with poor treatment response
    Nagaya, N.
    Kanayama, M.
    Nagata, M.
    Horie, S.
    ANNALS OF ONCOLOGY, 2017, 28 : 78 - 78
  • [7] Relationship between abiraterone exposure, prostate-specific antigen (PSA) kinetics, and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Xu, Steven
    Ryan, Charles J.
    Stuyckens, Kim
    Smith, Matthew R.
    Saad, Fred
    Griffin, Thomas W.
    Park, Youn Choi
    Yu, Margaret K.
    Vermeulen, An
    Poggesi, Italo
    Nandy, Partha
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [8] CIRCULATING TUMOR CELLS (CTC) AND PROSTATE-SPECIFIC ANTIGEN (PSA) AS RESPONSE INDICATOR BIOMARKERS IN CHEMOTHERAPY-NAIVE PATIENTS WITH PROGRESSIVE CASTRATION-RESISTANT PROSTATE CANCER (CRPC) TREATED WITH MDV3100
    Hirmand, M.
    Scher, H. I.
    Beer, T.
    Higano, C. S.
    Taplin, M.
    Efstathiou, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 277 - 277
  • [9] Response to cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) poorly responding to docetaxel
    Angelergues, A.
    Bellmunt, J.
    Efstathiou, E.
    Gonzalez, I.
    Gyftaki, R.
    Delanoy, N.
    Ozguroglu, M.
    Flechon, A.
    Guillot, A.
    Le Moulec, S.
    Castellano, D.
    Esteban, E.
    Munarriz, J.
    Campos Balea, B.
    Ardavanis, A.
    Stefanou, D.
    Oudard, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S488 - S488
  • [10] Prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer
    Kanao, Kent
    Ito, Toshiki
    Takahara, Kiyoshi
    Ando, Ryosuke
    Yasui, Takahiro
    Shiroki, Ryoichi
    Miyake, Hideaki
    Sumitomo, Makoto
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (11) : 1043 - 1048
12345